Join Morrison Foerster and University of Minnesota Technology Commercialization and Center for Precision Plant Genomics for a webinar exploring the overlapping roles of USDA, FDA, and EPA in the regulation of gene edited plants.
Gene editing has the potential to revolutionize agriculture and food production, but innovators in this sector must navigate a complex regulatory landscape to successfully commercialize a product. In the United States, gene edited plants are regulated under a coordinated framework governed by USDA, FDA, and EPA, and it is critical that scientists, entrepreneurs, and investors in this sector have an understanding of the role each agency plays. In this program, MoFo’s leading patent, FDA, and EPA lawyers will provide an overview of how these agencies intersect and important recent regulatory developments.
Topics of discussion include:
- How USDA, FDA, and EPA work together to regulate gene edited plants and foods produced therefrom
- Strategic considerations for addressing USDA’s SECURE rule
- Developments in regulations addressed at the recent USDA-BRS Stakeholder Meeting in December 2022
Speakers:
- Michael Ward, Ph.D., Partner & Chair, Plant Intellectual Property, Life Sciences, and Patent Groups; Co-chair, IP and Food + Agriculture Groups, Morrison Foerster
- Stacy Cline Amin, Partner & Chair, FDA + Healthcare Regulatory and Compliance Group, Morrison Foerster, former FDA Chief Counsel and Deputy General Counsel of the Department of Health and Human Services
- Brigid Bondoc, Partner, FDA + Healthcare Regulatory and Compliance Group, Morrison Foerster
- Bill Tarantino, Partner, EPA Regulatory Strategist, Morrison Foerster